Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pär Stattin"'
Autor:
Montse Soriano Gabarró, Jihong Zong, Juha Mehtälä, Houssem Khanfir, Gunnar Brobert, Zdravko P. Vassilev, Pär Stattin
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0227552 (2020)
PLoS ONE
PLoS ONE
Background Among prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. PC treatments may be associated with side effects, including second primary malignancies (SPM). There is limited information on the incidence of SPM amo
Autor:
Elin Thysell, Maria Nilsson, Sofia Halin Bergström, Anders Bergh, Anders Widmark, Emma Jernberg, Pernilla Wikström, Pär Stattin, Hanibal Hani Adamo
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157280 (2016)
PLoS ONE
PLoS ONE
Aggressive tumors induce tumor-supporting changes in the benign parts of the prostate. One factor that has increased expression outside prostate tumors is hemoxygenase-1 (HO-1). To investigate HO-1 expression in more detail, we analyzed samples of tu
Autor:
Pär Stattin, Pernilla Andersson, Pernilla Wikström, Anders Bergh, Lars Egevad, Peter Hammarsten, Torvald Granfors, Tove Dahl Scherdin, Christina Hägglöf
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0164016 (2016)
PLoS ONE
PLoS ONE
In the present study we have investigated whether Caveolin-1 expression in non-malignant and malignant prostate tissue is a potential prognostic marker for outcome in prostate cancer patients managed by watchful waiting. Caveolin-1 was measured in pr
Autor:
Sofia Halin Bergström, Peter Hammarsten, Maria Nilsson, Elin Thysell, Torvald Granfors, Lars Egevad, Christina Hägglöf, Anders Bergh, Emma Jernberg, Pernilla Wikström, Pär Stattin
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140985 (2015)
PLoS ONE
PLoS ONE
Lysyl oxidase (LOX) has been shown to both promote and suppress tumor progression, but its role in prostate cancer is largely unknown. LOX immunoreactivity was scored in prostate tumor epithelium, tumor stroma and in the tumor-adjacent non-malignant
Autor:
Hans Garmo, Andreas Thorstenson, Lars Holmberg, Olof Akre, Mieke Van Hemelrijck, Karl Michaëlsson, Jan Adolfsson, Pär Stattin
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74492 (2013)
PLoS ONE
PLoS ONE
Background: Hip fractures are associated with increased mortality and are a known adverse effect of androgen deprivation therapy (ADT) for prostate cancer (PCa). It was our aim to evaluate how mortality after hip fracture is modified by PCa and ADT.
Autor:
Lars Egevad, Andreas Josefsson, Peter Hammarsten, Pär Stattin, Torvald Granfors, Christopher J. Fowler, Mariateresa Cipriano
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e47994 (2012)
PLoS ONE
PLoS ONE
BACKGROUND: In the present study, we have investigated the prognostic usefulness of phosphorylated Akt immunoreactivity (pAkt-IR) in prostate cancer using a well-characterised tissue microarray from men who had undergone transurethral resection due t
Autor:
Christopher J. Fowler, Anders Bergh, Lina Thors, Emma Persson, Lars Egevad, Pär Stattin, Torvald Granfors, Peter Hammarsten
Publikováno v:
PLoS ONE, Vol 5, Iss 8, p e12275 (2010)
PLoS ONE
PLoS ONE
Background Recent data have indicated that there may be a dysregulation of endocannabinoid metabolism in cancer. Here we have investigated the expression of the endocannabinoid metabolising enzyme fatty acid amide hydrolase (FAAH) in a well character